Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research , National Cancer Institute, National Institutes of Health , Bethesda , Maryland 20892 , United States.
J Med Chem. 2019 May 9;62(9):4669-4682. doi: 10.1021/acs.jmedchem.9b00274. Epub 2019 Apr 30.
Topoisomerase II (TOP2) poisons as anticancer drugs work by trapping TOP2 cleavage complexes (TOP2cc) to generate DNA damage. Repair of such damage by tyrosyl DNA phosphodiesterase 2 (TDP2) could render cancer cells resistant to TOP2 poisons. Inhibiting TDP2, thus, represents an attractive mechanism-based chemosensitization approach. Currently known TDP2 inhibitors lack cellular potency and/or permeability. We report herein two novel subtypes of the deazaflavin TDP2 inhibitor core. By introducing an additional phenyl ring to the N-10 phenyl ring (subtype 11) or to the N-3 site of the deazaflavin scaffold (subtype 12), we have generated novel analogues with considerably improved biochemical potency and/or permeability. Importantly, many analogues of both subtypes, particularly compounds 11a, 11e, 12a, 12b, and 12h, exhibited much stronger cancer cell sensitizing effect than the best previous analogue 4a toward the treatment with etoposide, suggesting that these analogues could serve as effective cellular probes.
拓扑异构酶 II (TOP2) 抑制剂作为抗癌药物,通过捕获 TOP2 切割复合物 (TOP2cc) 来产生 DNA 损伤而起作用。酪氨酸 DNA 磷酸二酯酶 2 (TDP2) 对这种损伤的修复可能使癌细胞对 TOP2 抑制剂产生耐药性。因此,抑制 TDP2 代表了一种有吸引力的基于机制的化疗增敏方法。目前已知的 TDP2 抑制剂缺乏细胞效力和/或通透性。我们在此报告了两种新型的去氮黄素 TDP2 抑制剂核心亚型。通过在 N-10 苯基环(亚型 11)或去氮黄素支架的 N-3 位引入额外的苯基环(亚型 12),我们生成了具有显著提高的生化效力和/或通透性的新型类似物。重要的是,这两种亚型的许多类似物,特别是化合物 11a、11e、12a、12b 和 12h,在与依托泊苷联合治疗时,对癌细胞的增敏作用比之前最好的类似物 4a 强得多,这表明这些类似物可以作为有效的细胞探针。